Notably, IMC demonstrated a higher proportion of HLA-DR+ cancer cells in responders than nonresponders after monotherapy atezolizumab (Supplementary Fig. 4c), which is in line with the increased IFNγ signaling in responders43. Here, IFNG is linked to cancer.